Stocks Health care RLMD
NASDAQ · Health careRelmada Therapeutics, Inc. (RLMD)
It posted a net loss of $61.9M. At June 30, 2026 it held $11.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Relmada Therapeutics, Inc.
- Net worth
- Relmada Therapeutics, Inc. has a market value (market cap) of $441.6M at the latest share price, and shareholders' equity of $206.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $45.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Relmada Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Relmada Therapeutics, Inc. does
Relmada Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RLMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$57.4M | -$1.45 | n/a |
| 2024 | n/a | -$80M | -$2.65 | n/a |
| 2023 | n/a | -$98.8M | -$3.28 | n/a |
| 2022 | n/a | -$157M | -$5.30 | n/a |
| 2021 | n/a | -$125.8M | -$7.16 | n/a |
| 2020 | n/a | -$59.5M | -$3.81 | -$209.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Relmada Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 28, 2026
- June 22, 2026Passive stake (5% or more) SCHEDULE 13G
- June 18, 2026
- June 9, 2026Passive stake (5% or more) SCHEDULE 13G
- May 28, 2026
Insider trades
What the people running Relmada Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $1.7M worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Traversa SergioChief Executive Officer, Director | Bought | 100,000 | $410K |
| September 10, 2026 | Shenouda MagedChief Financial Officer | Bought | 79,800 | $339.2K |
| September 9, 2026 | Traversa SergioChief Executive Officer, Director | Bought | 100,000 | $418K |
| September 9, 2026 | Shenouda MagedChief Financial Officer | Bought | 120,200 | $504.8K |
| December 15, 2025 | Shenouda MagedChief Financial Officer | Bought | 11,665 | $48.1K |
| December 15, 2025 | Traversa SergioChief Executive Officer, Director | Bought | 27,500 | $113.3K |
Who owns RLMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive | 10.1% | February 6, 2026 |
| Squadron Master Fund LP13G, passive with 3 related filers | 7% | August 14, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 6.2% | June 9, 2026 |
| Spruce Street Capital LP13G, passive with 2 related filers | 5.57% | February 17, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 5.1% | May 4, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 126 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 11,164,803 | new |
| BlackRock, Inc. | 7,426,780 | +6,137,230 |
| Squadron Capital Management LLC | 7,350,000 | -1,124,571 |
| Venrock Adviser, LLC | 6,844,305 | +2,000,925 |
| Spruce Street Capital LP | 6,391,328 | +129,214 |
| Adage Capital Partners GP, L.L.C. | 4,763,158 | 0 |
| Vanguard Capital Management LLC | 4,460,210 | +1,383,640 |
| Jones Hill Capital LP | 3,655,075 | +3,312,323 |
| Orbimed Advisors LLC | 3,631,195 | -1,084,669 |
| State Street Corp | 2,517,550 | +2,160,510 |
| Geode Capital Management, LLC | 2,492,573 | +1,643,890 |
| Millennium Management LLC | 2,361,827 | -1,545,438 |
| Marshall Wace, Llp | 2,246,839 | -2,234,767 |
| Ikarian Capital, LLC | 2,148,359 | -540,000 |
| Driehaus Capital Management LLC | 2,132,053 | 0 |
| Ameriprise Financial Inc | 1,937,972 | +347,026 |
| Eventide Asset Management, LLC | 1,858,416 | +1,016,310 |
| Balyasny Asset Management L.P. | 1,520,688 | +1,268,231 |
| Stempoint Capital LP | 1,460,093 | +265,275 |
| Commodore Capital LP | 1,425,000 | +791,099 |
Insiders
2 insiders reported holding 2,500,000 shares in total, about $10.4M at the last price.
| Holder | Shares |
|---|---|
| Traversa SergioChief Executive Officer, Director | 1,500,000 |
| Shenouda MagedChief Financial Officer | 1,000,000 |
Questions about RLMD
What does Relmada Therapeutics, Inc. do?
Relmada Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as RLMD. Its shares trade on NASDAQ under the ticker RLMD.
What is Relmada Therapeutics, Inc.'s net worth?
Relmada Therapeutics, Inc. has a market value (market cap) of $441.6M at the latest share price, and shareholders' equity of $206.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Relmada Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $61.9M.
When did Relmada Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 11, 2026.
When is Relmada Therapeutics, Inc.'s next earnings report?
Relmada Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RLMD with
Follow RLMD
Get an email when Relmada Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Relmada Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.